Lunai Bioworks Inc（LNAI）財務資料LNAILunai Bioworks Inc

Evaluating the bottom line, Lunai Bioworks Inc maintains a gross margin of 4.45%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -6888.56%, while the net margin is -6475.69%. These profitability ratios, combined with a Return on Equity (ROE) of 76.07%, provide a clear picture of how effectively LNAI converts its operational activities into shareholder value.

In the context of the broader market, LNAI competes directly with industry leaders such as LABT and OGCP. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, LNAI's gross margin of 4.45% stands against LABT's N/A and OGCP's N/A. Such benchmarking helps identify whether Lunai Bioworks Inc is trading at a premium or discount relative to its financial performance.

Lunai Bioworks has shown no revenue generation in several quarters, with total revenue reported as $0.00 for Q2 and Q3 of 2025, and only $20,942 in Q3 of 2026. The net income has been negative for most quarters, with a significant loss of $126,732,236 in Q4 2025 and a loss of $2,571,394 in Q3 2026. The gross margin is only 4.45% projected for Q1 2027, which is very low.